

CV Brief 2004

Name **Jaime Kulisevsky**
Department Department of Neurology – Sant Pau Hospital, Barcelona, Spain
University Universitat Autònoma de Barcelona (UAB)
Email: jkulisevsky@santpau.cat

POSITION TITLE

Director, Movement Disorders Unit – Neurology Department, Sant Pau Hospital, Barcelona
Full Professor of Neurology – Universitat Autònoma de Barcelona (UAB)

Education

<i>Institution and Location</i>	<i>Degree</i>	<i>Date</i>	<i>Field of Study</i>
University of Barcelona, Spain	M.D.	1981	Medicine
Autonomous University of Barcelona	Ph.D.	1992	Neuroscience

Professional Preparation

1982 – 1985 Certified Board in Clinical Neurology (Catalan Institute of Health, MIR)

Professional Experience:

1982-1985 Training in Neurology, Sant Pau Hospital (SPH), Barcelona, Spain
1986-1987 Neurology Department, Clinic Hospital- University of Barcelona (UB)
1988-1989 Neurology Department, Trias i Pujol Hospital - UAB
1989- 2007 Neurology Department, Sant Pau Hospital - UAB
1997- present Chair, Functional Neurosurgery Program for Movement Disorders
1999-2003 Section Chief, Movement Disorders Unit – Sant Pau Hospital
2003-present Director, Movement Disorders Unit – Sant Pau Hospital
2008-2019 Director, Biomedical Research Institute Sant Pau Hospital (IIB Sant Pau)
2020-present Director, Clinical School of Neuropsychology & Language Pathology (SPH)

Academic Ranks

1999–present Director, 'Master Degree in Neuropsychological Diagnosis (UAB)
2008–2019 Associate Professor of Neurology - Autonomous University of Barcelona
2014-2017 Research Professor - UOC (Open University of Catalonia)
2020 –present Full Professor of Neurology - Autonomous University of Barcelona
2018- present Vice-Dean Faculty of Medicine - Autonomous University of Barcelona

Positions in Professional Societies

1999 - 2000 Chair of the Movement Disorders Section of the Spanish Society of Neurology
2000 - 2002 Member of the Educational Committee of the Spanish Neurological Society
2009 - 2019 Member of the MDS Task Force for Developing Rating Scales in Parkinson's disease (MDS – UPDRS)
2007- 2009 Member of the Education in Europe Working Group (EiEWG) – MDS
2009 - 2011 Member of the Executive Committee of the MDS European Section (MDS-ES)
2010 - 2012 Member of the MDS Web Site Editorial Board
2009 - 2013 Member of the Award Committee of the Movement Disorders Society
2009 - 2011 Member of the MDS Task Force for Mild cognitive Impairment in PD
2015 – 2021 Member of the MDS Task Force Recommendations for the Management of Huntington's disease
2019 - 2021 European Section Officers of the MDS
2019 – 2023 Member of the Financial Affairs Committee of the Movement Disorders Society
2021- 2023 European Section Officers & Treasurer of the MDS-ES
2019 – present Member of the Executive Committee of the European Huntington Disease Network (EHDN)
2021 – 2023 Member of the MDS Task Force 'MDS Criteria for PD – Clinical'
2018 - present Chairman of the 'Cognitive Phenotype Working Group' of the EHDN

Scientific and Academic Committees:

2012-2014 Scientific Advisor of the Michael J. Fox Foundation for Parkinson's Disease
2012-present Spanish Coordinator of the international clinical research platform ENROLL-HD
2002-present Reviewer of biomedical projects of the Spanish State Investigation Agency

Main Awards

2009 'Corresponding Academic', Royal Academy of Medicine of Murcia (Spain)
2011 Scientific Prize of the Year 2010, Spanish Neurological Society
2020 Board of Trustees of the Biomedical Research Institute (Sant Pau Hospital)
2021 Fellow of the European Academy of Neurology (FEAN)

Journal Editor

Movement Disorders Editor, Revista de Neurología (Spain)
Frontiers in Movement Disorders, Associate Editor

Current grant support:

2007- Present Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED) Research Program in Parkinson's Disease
2022 – 2024 Support to Research Groups Established in Catalonia (Generalitat of Catalonia)

Principal Investigator of Current public active grants:

- Multicenter, randomized, double-blind, and placebo-controlled clinical trial to evaluate the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's Disease. Carlos III Health Institute. 2023-2025. €575,000.
- Research and development of a new therapy for the treatment of Huntington's disease (Public-Private Collaboration Projects). Ministry of Science and Innovation. Research. 2023-2025. €625,386.
- Development and validation of specific cognitive assessment instruments based on the biology of Huntington's disease. Carlos III Health Institute. 2022-2025. €244,420.

More Recent Publications on Huntington 's disease (corresponding author)

- Martínez-Horta S, Perez-Perez J, Perez-Gonzalez R, Sampedro F, Horta-Barba A, Campolongo A, Rivas-Asensio E, Puig-Davi A, Pagonabarraga J, **Kulisevsky J**. Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease. Ann Clin Transl Neurol. 2024 Mar 27. doi: 10.1002/acn3.52031. Epub ahead of print.
- Aracil-Bolaños I, Pérez-Pérez J, Martínez-Horta S, Horta-Barba A, Puig-Davi A, García-Cornet J, Olmedo-Saura G, Campolongo A, Pagonabarraga J, **Kulisevsky J**. Baseline Large-Scale Network Dynamics Associated with Disease Progression in Huntington's Disease. Mov Disord. 2024 Jan;39(1):197-203.
- Martínez-Horta S, Perez-Perez J, Oltra-Cucarella J, Sampedro F, Horta-Barba A, Puig-Davi A, Pagonabarraga J, **Kulisevsky J**. Divergent cognitive trajectories in early stage Huntington's disease: A 3-year longitudinal study. Eur J Neurol. 2023 Jul;30(7):1871-1879.
- Martínez-Horta S, Aracil-Bolaños I, Perez-Perez J, Perez-Carasol L, Garcia-Cornet J, Campolongo A, Aibar-Duran JA, Rodriguez-Rodriguez R, Pascual-Sedano B, **Kulisevsky J**. Theta/Alpha Band Suppression and Clinical Outcomes During Globus Pallidus Internus Deep Brain Stimulation in Huntington's Disease. Mov Disord Clin Pract. 2023 Jan 10;10(3):518-520.
- Horta-Barba A, Martínez-Horta S, Sampedro F, Pérez-Pérez J, Camacho V, Pagonabarraga J, **Kulisevsky J**. Structural and metabolic brain correlates of arithmetic word-problem solving in Huntington's disease. J Neurosci Res. 2023 Jun;101(6):990-999.
- Gamez J, Calopa M, Muñoz E, Ferré A, Huertas O, McAllister K, Reig N, Scart-Grès C, Insa R, **Kulisevsky J**. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. Br J Clin Pharmacol. 2023 May;89(5):1656-1664.
- Martínez-Horta S, Perez-Perez J, **Kulisevsky J**. Koro-like syndrome in Huntington's disease. Rev Psiquiatr Salud Ment. 2023 May 25:S1888-9891(23)00007-1.